Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Cilloni

Showing results (91-100 of 193) with videos related to

Pageof 20
Sort By:
Blood Advances|November 5, 2025
UBE2O AS A KEY REGULATOR OF DRUG-INDUCED ERYTHROPOIESIS IN THE CONTEXT OF MYELODYSPLASTIC SYNDROMESBeatrice Maffeo, Cristina Panuzzo, Arianna Savi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapySerena Merante, Merante Serena, Guido Chichino, et al.
Cancer|August 27, 2004
Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubationDaniela Cilloni, Francesca Messa, Enrico Gottardi, et al.
Oncotarget|December 30, 2016
A novel assay to detect calreticulin mutations in myeloproliferative neoplasmsValentina Rosso, Jessica Petiti, Enrico Bracco, et al.
Journal of Clinical Medicine|August 26, 2023
Italian Physicians' Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA SurveyMassimo Breccia, Alfonso Piciocchi, Elisabetta Abruzzese, et al.
British Journal of Haematology|July 10, 2018
The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinibElena Crisà, Daniela Cilloni, Elena M Elli, et al.
American Journal of Hematology|June 20, 2015
Development of cellular and humoral response against WT1 protein vaccination in micePaolo Nicoli, Chiara Calabrese, Rosa Maria Pellegrino, et al.
Leukemia & Lymphoma|May 10, 2017
Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective studyEmanuela Messa, Lucia Biale, Anna Castiglione, et al.
Oncotarget|October 22, 2016
Variable but consistent pattern of Meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detectionSonia Carturan, Jessica Petiti, Valentina Rosso, et al.
Journal of Clinical Medicine|May 17, 2020
Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical <i>BCR-ABL1</i> TranscriptsJessica Petiti, Marco Lo Iacono, Matteo Dragani, et al.
Pageof 20

Showing results (91-100 of 193) with videos related to

Sort By:
Pageof 20
Blood Advances|November 5, 2025
UBE2O AS A KEY REGULATOR OF DRUG-INDUCED ERYTHROPOIESIS IN THE CONTEXT OF MYELODYSPLASTIC SYNDROMESBeatrice Maffeo, Cristina Panuzzo, Arianna Savi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapySerena Merante, Merante Serena, Guido Chichino, et al.
Cancer|August 27, 2004
Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubationDaniela Cilloni, Francesca Messa, Enrico Gottardi, et al.
Oncotarget|December 30, 2016
A novel assay to detect calreticulin mutations in myeloproliferative neoplasmsValentina Rosso, Jessica Petiti, Enrico Bracco, et al.
Journal of Clinical Medicine|August 26, 2023
Italian Physicians' Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA SurveyMassimo Breccia, Alfonso Piciocchi, Elisabetta Abruzzese, et al.
British Journal of Haematology|July 10, 2018
The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinibElena Crisà, Daniela Cilloni, Elena M Elli, et al.
American Journal of Hematology|June 20, 2015
Development of cellular and humoral response against WT1 protein vaccination in micePaolo Nicoli, Chiara Calabrese, Rosa Maria Pellegrino, et al.
Leukemia & Lymphoma|May 10, 2017
Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective studyEmanuela Messa, Lucia Biale, Anna Castiglione, et al.
Oncotarget|October 22, 2016
Variable but consistent pattern of Meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detectionSonia Carturan, Jessica Petiti, Valentina Rosso, et al.
Journal of Clinical Medicine|May 17, 2020
Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical <i>BCR-ABL1</i> TranscriptsJessica Petiti, Marco Lo Iacono, Matteo Dragani, et al.
Pageof 20